Bristol-myers Squibb Stock News

"The Big Short" investor has raised a lot of eyebrows with his latest trade.

These two drug makers have outshined the market this year.

Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.

August 10, 2022 -- InvestorsHub NewsWire --NetworkNewsWire Editorial Coverage: In medicine, there is a term called "clinical inertia," or the case of what someone doesn't know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disease. It is particularly appropriate with a silent killer such as hypertension, a condition that all too often goes untreated, becoming a culprit in morbidity and mor...

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

Bristol Myers Squibb is attractive with a 10% earnings yield, 3% dividend yield, and tenacious performance over the last several quarters. Growth is lacking as BMY is losing market share to generic al

Bristol Myers Squibb stock (NYSE: BMY) reported its Q2 results last week, with revenue and earnings coming in above ours and the street estimates.

When the market is falling, this trio keeps rising.

Income investors have a lot to like about these stocks.

Will Bristol-Myers Squibbs' pipeline and newly approved drugs overcome its expiring patents?

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

BMY lowered its full-year guidance due to currency headwinds. However, the portfolio performed as expected, and the company reported a number of important advances. Revlimid sales declined in line wit

A looming patent cliff puts pressure on the company's newest products.

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Giovanni Caforio - Board Chair &

Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.